| | | | | | | | | | | | | | | | |
| |
| Issue Date FY: 2024 ( Subtotal = $67,038,192 ) (Continued on the next page) |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01LM013352 | Statistical Methods and Validation Analyses for the Integration of External Data in Clinical Trials | 000 | 4 | NIH | 12/29/2023 | $338,565 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA251555 | Elucidation of the genetic mechanisms driving prostate tumorigenesis through integrative computational and functional approaches | 000 | 4 | NIH | 3/25/2024 | $607,347 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA251555 | Elucidation of the genetic mechanisms driving prostate tumorigenesis through integrative computational and functional approaches | 001 | 4 | NIH | 4/24/2024 | $33,743 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA259365 | Structure-activity relationships governing mammalian SWI/SNF chromatin remodeling activity as a function of chromatin state | 001 | 4 | NIH | 4/16/2024 | $34,517 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA259365 | Structure-activity relationships governing mammalian SWI/SNF chromatin remodeling activity as a function of chromatin state | 000 | 4 | NIH | 3/29/2024 | $621,332 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K08CA259623 | Elucidating the impact of DNA hypomethylation on genome organization and anti-tumor transcriptional programs | 000 | 5 | NIH | 3/11/2024 | $195,134 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA258924 | Genetic Predisposition to Chronic Lymphocytic Leukemia (CLL) | 000 | 4 | NIH | 3/20/2024 | $532,020 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA258688 | Optimizing Therapeutic STING Agonism in Triple Negative Breast Cancer | 001 | 4 | NIH | 4/16/2024 | $20,359 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA258688 | Optimizing Therapeutic STING Agonism in Triple Negative Breast Cancer | 000 | 4 | NIH | 3/20/2024 | $366,458 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA258924 | Genetic Predisposition to Chronic Lymphocytic Leukemia (CLL) | 001 | 4 | NIH | 4/16/2024 | $29,556 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K08CA252639 | Can a subset of patients with HER2+ metastatic breast cancer be cured? | 000 | 4 | NIH | 3/20/2024 | $258,561 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA251470 | Yoga for Chemotherapy-induced Peripheral Neuropathy Treatment (YCT) Trial | 005 | 5 | NIH | 4/17/2024 | $36,648 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA251470 | Yoga for Chemotherapy-induced Peripheral Neuropathy Treatment (YCT) Trial | 004 | 5 | NIH | 3/4/2024 | $659,678 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | P01AI181597 | RNA-based HIV-1 chimera vaccines encoding a trimerizing host self-protein protomer linked to a viral MPER-TM segment | 000 | 1 | NIH | 3/28/2024 | $2,356,969 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R00CA266921 | SESORRS endoscopy for the staging and evaluation of colorectal cancer | 000 | 3 | NIH | 1/5/2024 | $248,999 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99CA283154 | Targeting mitochondrial vulnerabilities to drive intrinsic melanoma immunogenicity | 000 | 1 | NIH | 4/4/2024 | $128,798 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F32CA284750 | Investigating IGF2BP1 as a novel Therapeutic Target for Ewing Sarcoma | 000 | 1 | NIH | 4/3/2024 | $69,080 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R21CA279278 | Sexual Health and Rehabilitation (SHARE): An Online Educational Intervention for Young Adult Female Cancer Survivors | 000 | 1 | NIH | 3/1/2024 | $255,280 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R21CA288234 | Investigating Interactions Between Radiation and Antibody-Drug Conjugates in Bladder Cancer | 000 | 1 | NIH | 4/8/2024 | $206,067 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K08CA282965 | BCOR/PRC1.1 Inactivation In Splicing Factor Mutant MDS Progression | 000 | 1 | NIH | 4/8/2024 | $250,507 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | P01CA269021 | Targeting Replication Stress and DNA Damage Response in Uterine Cancer | 000 | 1 | NIH | 4/8/2024 | $2,971,802 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99CA287050 | Harnessing Exercise to Enhance Immunity and Boost Immunotherapy Outcomes in Patients with Lung Cancer | 000 | 1 | NIH | 1/18/2024 | $163,448 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA289304 | Dissecting and Targeting MAPK - PPARG Crosstalk in Bladder Cancer | 000 | 1 | NIH | 4/5/2024 | $497,544 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R13AI183717 | Symposium on the Immune System of Bacteria | 000 | 1 | NIH | 3/5/2024 | $7,500 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA279391 | Merkel cell polyomavirus HLA class I epitopes for generating therapeutic T cell-based cancer immunotherapy | 000 | 1 | NIH | 1/9/2024 | $735,360 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K08HD109453 | Identifying metabolic regulation of T cells during early childhood development | 000 | 1 | NIH | 3/21/2024 | $165,240 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01HL171973 | Molecular mechanisms of splicing dependency in cohesin-mutant myelodysplasia | 000 | 1 | NIH | 12/1/2023 | $445,000 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K08CA279891 | Epigenetic regulators define a dynamic chromatin landscape in NUP98-rearranged leukemia | 000 | 1 | NIH | 3/25/2024 | $215,179 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA289547 | Randomized trial of REVITALIZE: A telehealth intervention to reduce fatigue interference among adults with advanced ovarian cancer on PARP inhibitors | 000 | 1 | NIH | 4/19/2024 | $748,174 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R21CA286345 | In vivo testing of an agonistic anti-GITR mAb that induces cell surface clustering to augment signal transduction and a 2nd Gen bispecific anti-GITR/PD1 Ab derivative for improved anti-tumor activity | 000 | 1 | NIH | 1/24/2024 | $268,059 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01AG075837 | Contribution of a novel OPN-producing CD11c+ microglial subset to AD | 000 | 1 | NIH | 1/16/2024 | $505,974 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R61CA278449 | New Chemical Tools for Covalent Drug Discovery | 000 | 1 | NIH | 1/30/2024 | $249,647 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K00CA264296 | Exploiting Oncogenic Chromatin Regulators in Cancer Initiation and Progression | 000 | 3 | NIH | 12/21/2023 | $92,304 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99CA286805 | Dissecting the Role of Germline Genetics in RAS-Driven Cancers | 000 | 1 | NIH | 1/19/2024 | $163,728 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R03DK138231 | The role of the mesenchymal niche in intestinal crypt fission | 000 | 1 | NIH | 2/7/2024 | $125,700 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U01CA286537 | Mechanism and functional consequences of dietary lipids in lineage specification and tumor growth in oncohistone gliomas | 000 | 1 | NIH | 3/12/2024 | $721,959 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA279221 | Dissecting Integrated Cellular Programs Promoting Platinum Resistance and Progression in Bladder Cancer | 000 | 1 | NIH | 2/15/2024 | $736,801 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA279414 | A multi-level examination of the influences of racism on cancer pain equity | 000 | 1 | NIH | 2/21/2024 | $775,031 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01GM152499 | Survival Data Analysis using general censoring-free incident rate | 001 | 1 | NIH | 4/8/2024 | $0 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01GM152499 | Survival Data Analysis using general censoring-free incident rate | 000 | 1 | NIH | 2/15/2024 | $347,254 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA278980 | Dissecting Convergent Somatic and Germline Alterations that Mediate the Origins and Evolution of Kidney Cancer | 000 | 1 | NIH | 12/29/2023 | $728,817 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99CA279888 | Targeting Menin Protein Stability In AML | 000 | 2 | NIH | 3/12/2024 | $129,600 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K23NR020219 | Development and Pilot Testing of a Collaborative Agenda-Setting Intervention to Promote Patient-Centered Communication in Ovarian Cancer Care | 000 | 2 | NIH | 4/19/2024 | $133,757 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA270040 | BOLSTER: Strengthening Patient and Caregiver Supports in Advanced Gynecologic and Gastrointestinal Cancers - a Multi-Site Randomized Controlled Trial | 001 | 2 | NIH | 4/16/2024 | $34,924 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA270040 | BOLSTER: Strengthening Patient and Caregiver Supports in Advanced Gynecologic and Gastrointestinal Cancers - a Multi-Site Randomized Controlled Trial | 000 | 2 | NIH | 1/5/2024 | $628,653 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99HG012798 | Robust and cost-effective computational methods for haplotype-resolved genome assemblies | 000 | 2 | NIH | 1/17/2024 | $122,262 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R37CA269990 | Mechanisms by which LSD1 Promotes Neuroendocrine Differentiation and Small Cell Lung Cancer | 001 | 2 | NIH | 4/24/2024 | $22,995 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R37CA269990 | Mechanisms by which LSD1 Promotes Neuroendocrine Differentiation and Small Cell Lung Cancer | 000 | 2 | NIH | 11/3/2023 | $413,929 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | UG3NS132127 | Single Molecule Detection of L1 Insertions and Intermediates | 000 | 2 | NIH | 4/25/2024 | $428,166 |
|